Showing 7241-7250 of 9747 results for "".
- Alumis Closes $259 Million Financing to Help Launch Phase 3 Psoriasis Trial for Lead Asset ESK-001https://practicaldermatology.com/news/alumis-closes-259-million-financing-to-help-launch-phase-3-psoriasis-trial-for-lead-asset/2462267/In this year's largest privite biotech fundraise to date, Alumis announced $259 million Series C financing to initiate pivotal phase 3 clinical trials for its lead candidate ESK-001, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe pl
- Cyndi Lauper to Host New Novartis PsO Podcasthttps://practicaldermatology.com/news/cyndi-lauper-to-host-new-novartis-pso-podcast/2460514/Novartis is launching PsO in the Know, a podcast series hosted by music icon Cyndi Lauper. PsO in the Know will feature a variety of guests, including Chef Aarón Sánchez, actress and New York Times best-selling author La La Anthony, and Emmy
- Botox Hits the Big 3-0https://practicaldermatology.com/news/botox-hits-the-big-3-0/2460184/Botox is turning 30, and Allergan fêted its shining star, Botox Cosmetic, in style at a New York City bash. The event included the debut of Botox Cosmetic’s new packaging and a panel discussion featuring New York City dermatologists Macrene Alexiades-Armenakas, MD, PhD
- L'Oréal Debuts Wearable Electronic UV Monitorhttps://practicaldermatology.com/news/loral-debuts-wearable-electronic-uv-monitor/2458740/Earlier this month at the Consumer Electronics Show, L’Oréal unveiled My UV Patch, a stretchable skin sensor designed to monitor UV exposure and help consumers educate themselves about sun protection. L’Oréal Group’s dermatological skincare brand, La Roche-Posay, i
- Market for Atopic Dermatitis Treatments to Surge Past $22 Billionhttps://practicaldermatology.com/news/market-for-atopic-dermatitis-treatments-to-surge-past-22-billion/2474524/The global atopic dermatitis (AD) market is projected to more than double over the next decade, reaching $22.37 billion by 2034, new research from Polaris Market Research indicates. Driven by an annual growth rate of 8.5%, the
- IEC Session Highlights AA/AD Connectionhttps://practicaldermatology.com/news/IEC-Session-Highlights-AA-AD-Connection/2471516/The International Eczema Council (IEC) meeting in advance of the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, was a crossover event. The IEC partnered with both the National Eczema Association (NEA) and National Alopecia Areata Foundation (NAAF) to present
- Novartis to Present CSU, HS Data for Remibrutinib, Secukinumabhttps://practicaldermatology.com/news/Novartis-Present-CSU-HS-Data-Remibrutinib-Secukinumab/2471383/Novartis announced it will present data from 17 abstracts, including investigator-initiated trials, across its immunology portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting and the 2025 American Academy of Allergy Asthma and Immunology (AAAAI) and World Allergy Organizatio
- Beyond the Surface: Updates in Itch Treatmenthttps://practicaldermatology.com/news/beyond-the-surface-updates-in-itch-treatment/2471285/
- LEVEL UP: Switching from Dupilumab to Upadacitinib Promising for AD Patientshttps://practicaldermatology.com/news/level-up-switching-from-dupilumab-to-upadacitinib-promising-for-ad-patients/2468483/New research presented at the 44th Annual Fall Clinical Dermatology Conference offered compelling results from th
- Study: Adherence Declines With Complex Atopic Dermatitis Regimenshttps://practicaldermatology.com/news/dherence-declines-complex-atopic-dermatitis-regimens-aad-guidelines/2468194/New American Academy of Dermatology (AAD) guidelines emphasize complex topical regimens for atopic dermatitis (AD), but adherence issues may limit their effectiveness, according to new research. According to a recent article in the Journal of Drugs in Dermatology, the AAD released